UK markets closed

Akebia Therapeutics, Inc. (AKBA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.4400-0.0400 (-2.70%)
At close: 04:00PM EDT
1.4491 +0.01 (+0.63%)
After hours: 07:50PM EDT
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
187,225
194,623
292,484
211,650
294,644
-
Cost of revenue
65,565
74,149
85,568
150,671
296,477
-
Gross profit
121,660
120,474
206,916
60,979
-1,833
-
Operating expenses
Research development
53,124
63,079
129,986
147,852
218,485
-
Selling general and administrative
100,618
100,233
138,601
174,140
154,099
-
Total operating expenses
157,122
166,549
271,762
325,481
375,993
-
Operating income or loss
-35,462
-46,075
-64,846
-264,502
-377,826
-
Interest expense
6,969
6,032
15,687
19,936
8,871
-
Total other income/expenses net
-603
182
-13,693
2,414
1,856
-
Income before tax
-43,034
-51,925
-94,226
-282,024
-384,841
-
Income tax expense
-
-
0
0
0
-6,631
Income from continuing operations
-43,034
-51,925
-94,226
-282,024
-384,841
-
Net income
-43,034
-51,925
-94,226
-282,024
-384,841
-
Net income available to common shareholders
-43,034
-51,925
-94,226
-282,024
-384,841
-
Basic EPS
-0.31
-0.28
-0.52
-1.70
-2.78
-
Diluted EPS
-0.31
-0.28
-0.52
-1.70
-2.78
-
Basic average shares
185,984
187,465
182,783
165,950
138,463
-
Diluted average shares
185,984
187,465
182,783
165,950
138,463
-